Semi-annual Report for 2026
Filed with SSE · · 190 pages · Chinese
Shanghai Pharmaceuticals Holding Co. Ltd. on 6ix
Earlier from Shanghai Pharmaceuticals
- Announcement on Resolutions of the 3rd Meeting of the 9th Board of Directors
- Announcement on Approval for Production of Omeprazole and Sodium Bicarbonate Dry Suspension (I)
- Announcement on Obtaining Canadian Product Licenses for DRAGON & TIGER Qingliang You Regular (Cooling Ointment), DRAGON & TIGER Qingliang You Ultra (Cooling Ointment) and DRAGON & TIGER Fengyou Jing Oil (Roll-On Medicated Oil)
- Announcement on Reply to the Shanghai Stock Exchange's Information Disclosure Supervisory Inquiry Letter on the Company's 2025 Annual Report
- Announcement on the Receipt of Clinical Trial Approval Notice for Qingrun Yangmu Granules
Later from Shanghai Pharmaceuticals
- Announcement on Approval for Production of Ruxolitinib Phosphate Tablets
- Announcement on Implementation of Dividend Distribution for the First Half of 2026
- Announcement on Approval for Production of Paclitaxel Injection
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Approval for Production of Esomeprazole Magnesium Enteric-coated Capsules
- (601607)"Shanghai Pharmaceuticals Holding Co., Ltd."Announcement on Approval for Production of Isavuconazonium Sulfate for Injection
Follow Shanghai Pharmaceuticals into a list and get an email when it puts out news.
Follow Shanghai Pharmaceuticals